Back

High rates of discontinuation and reinitiation of secondary preventive medications after a first myocardial infarction

30 August 2025 (08:15 - 09:00)
Organised by: Logo
Congress Presentation Part of: Risk factors and prevention (1) Secondary Prevention ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Ali Yari

Karolinska Institute, Stockholm (Sweden)

7 More presentations in this session

Presentation thumbnail
Incidence of metabolic syndrome and its association with hs-CRP and RC levels in a large cohort study
Associate Professor L. Bikdelu (Mashhad, IR)
Abstract Slides Video
Presentation thumbnail
Changing trends in myocardial infarction mortality among young adults in the United States: a 25-year analysis of disparities and the COVID-19 impact
Doctor N. Abou Khater (Abu Dhabi, AE)
Abstract Slides Video
Presentation thumbnail
THe Sub-Saharan Africa Survey of Heart Failure (THESUS-HF II): access to care
Doctor J. Hahnle (Cape Town, ZA)
Abstract Slides Video
Presentation thumbnail
Development of a multidimensional data-driven prediction model and risk stratification for 1-year cardiac mortality in AMI patients
Professor J. Wu (Harbin, CN)
Abstract Slides Video
Presentation thumbnail
Herpes zoster vaccine effectiveness against cardiovascular events - a systematic literature review and meta-analysis
Doctor C. Williams (Wavre, BE)
Abstract Slides Video

Access the full session

Session thumbnail
Risk factors and prevention (1)

The Event

Event poster

ESC Congress 2025

30 August 2025 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Long-term continuation to pharmacological treatment for secondary prevention after a myocardial infarction: a register study
thumbnail
Congress Presentation
Trajectories of adherence to secondary prevention pharmacotherapy after coronary angiography: a retrospective population-based study
thumbnail
Congress Presentation
Medication persistence and mortality in SWEDEHEART STEMI patients with and without standard modifiable risk factors

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources